2Randolph E R, Daryl D D, Heather L V. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital [J]. P harmacotherapy , 2003,23: 618.
3Drusano G L. Prevention of resistance: a goal for dose selection for antimicrobial agent [J]. Clin Infect Dis,2003,36(Suppl 1):42.
6Ateskan U,Mas MR,Yasar M,Deveci S,et al.Deferoxamine and meropenem combination therapy in experimental acute pancreatitis[J].Pancreas,2003,27(3):247-252.
7Verwaest C,iveName,Belgian Multicenter Study Group,CollectiveName.Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit[J].Clin Microbiol Infect,2000,6(6):294～302.
4Neu H, Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1982,21:11
5Mastella G, Agostini M, Barlocco G,et al. Alternative antibiotics for the treatment ofPseudomonas aeruginosa in cystic fibrosis[J]. J Antimicrob Chemother, 1983,12:297
6Livemore D M, William R J, William J D. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamase[J]. J Antimicrob Chemother, 1981,8:163
7Schassan Hh, Fredder J. Activity of ceftazidime and newer antibiotics against gram-negative bacilli [J]. J Antimicrob Chemother, 1981,8(supply B):79
8The Japanese pharmacopoeia [S].14th,Tokyo:Society of Japanse pharmacopoeia,2001:340
9Wright D B.Cefsulodin[J].Drug Intell Clin Pharm,1986,20(11):845
10Neu Hc. The new beta-lactamase-stable cephalosporins [J]. Ann Intern Med, 1982,97:408
